Lexeo completes acquisition of Mantle Therapeutics
The merger closed September 29, 2026, with Mantle now a wholly owned subsidiary, as Lexeo's SUNRISE-FA 2 trial continues toward 2H 2027 data.
SEC filing (2)
Latest
3 stories
Tuesday, September 29
Wednesday, August 12
Lexeo starts pivotal LX2006 trial, wins RMAT for LX2020
The company reported $234.2 million in cash as of June 30, 2026, and said it expects that to fund operations into 2028.
SEC filing